Tranzactioneaza Merck & Company (US.MRK) - 80.9 USD (%) Tranzactioneaza

Stiri

LPO (US.MRK) Impactata de tarife

Merck si-a redus estimarea de profit pentru intreg anul 2025, invocand costuri estimate la 200 mil. USD generate de tarifele vamale si un cost unic legat de un acord recent. Astfel, compania se asteapta acum ca profitul ajustat pe actiune sa fie intre 8.82 USD si 8.97 USD, in scadere fata de asteptarile anterioare de 8.88 USD – 9.03 USD. (Sursa: merck mrk earnings report q1 2025)

LPO (US.MRK) Achizitie importanta

Gigantul farmaceutic Merck se afla in discutii avansate pentru a achizitiona compania Harpoon Therapeutics pentru suma de 700 mil. USD. Conform calculelor, Merck va achita aproximativ 23 USD pentru fiecare actiune a companiei care produce tratamente pentru diferite tipuri de cancer. Dupa acest anunt, pretul actiunilor Harpoon Therapeutics s-a dublat in sedinta de pre-market, in timp ce al actiunilor Merck a inregistrat o scadere de 0.4%. (Sursa: articles)

BioNTech: achizitie istorica in aria Inteligentei Artificiale

BioNTech biontech acquire british artificial intelligence startup instadeep 01 102023 startup-ul britanic de inteligenta artificiala InstaDeep pentru 562 mil. GBP (aproximativ 682 mil. USD). Este cea mai mare achizitie din istoria companiei germane, destinata cresterii capacitatii de cercetare si productie privind tratamente revolutionare pe baza tehnologiei mRNA.

Pentru 2022, veniturile totale ale BioNTech biontech acquire british artificial intelligence startup instadeep 01 102023 estimate la 17 mld. EUR (aproximativ 18.2 mld. USD). Compania germana are lichiditati suficiente pentru a-si continua cercetarea in aria preventiei si tratarii unor afectiuni oncologice.

Pe 6 ianuarie, guvernul britanic biontech says it will start cancer vaccine trials in the uk from september 2023 un parteneriat cu BioNTech, destinat testarii unor vaccinuri potentiale contra mai multor afectiuni, inclusiv a celor oncologice, incepand din septembrie.

Si Moderna paradigm shift in cancer treatment as moderna mrna vaccine shows promise tot mai mult catre dezvoltarea unor vaccinuri contra cancerului, pe seama tehnologiei mRNA, inclusiv printr-o 2022 cu Merck. Primele rezultate obtinute in testele clinice sunt deja promitatoare.

(US.BNTX) (US.MRNA) (US.MRK)

BioNTech: primele teste clinice ale vaccinului contra cancerului

Guvernul britanic biontech says it will start cancer vaccine trials in the uk from september 2023 vineri un parteneriat cu BioNTech, destinat testarii unor vaccinuri potentiale contra mai multor afectiuni, inclusiv a celor oncologice, incepand din septembrie.

Si Moderna paradigm shift in cancer treatment as moderna mrna vaccine shows promise&nbsp tot mai mult catre dezvoltarea unor vaccinuri contra cancerului, pe seama tehnologiei mRNA, inclusiv printr-o 2022 cu Merck. Primele rezultate obtinute in testele clinice sunt deja promitatoare.

(US.BNTX) (US.MRNA) (US.MRK)

2 companii pe care le poti cumpara chiar acum (Biotech)


1. Merck (US.MRK) (FR.MRK)

Merck este cunoscut pentru cel mai bine vandut medicament pentru cancer din lume, Keytruda, care a produs vanzari uimitoare de 10.1 mld. USD in prima jumatate a acestui an.&nbsp

&nbsp 2. Sanofi (FR.SAN)

Capitalizarea pietei de 123 de mld. USD a Sanofi o pozitioneaza drept a patra cea mai mare companie farmaceutica cu sediul international si a 11-a cea mai mare companie farmaceutica de pe planeta.


2 top biotech stocks to buy right now2022


Merck Is in Advanced Talks to Buy Seagen for Roughly $40 Billion or More

Merck &amp Co. (US.MRK) is in advanced talks to acquire Seagen Inc. (US.SGENn) and is aiming to agree on a purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that could be worth roughly $40 billion or more.

The companies are discussing a price for Seagen above $200 a share and are seeking to seal a deal on or before the announcement of Merck’s quarterly earnings, set for July 28, the people said. Seagen’s stock closed at $175.13 on Wednesday.

There is still no guarantee the companies will reach agreement on a takeover deal.

articles

Jim Cramer picks 7 Dow stocks that investors should consider owning


Next, here is his list of the top five best-performing names in the Dow, with explanations for the stocks he gave investors his blessing to buy:&nbsp

  1. Chevron (US.CVX)&nbsp
  2. Merck (US.MRK): Cramer said the company is recession-proof, reports consistent earnings and has “juicy” dividends, which makes its stock worthy of investors’ cash — unless rates continue to go down.&nbsp
  3. Amgen (US.AMGN)&nbsp
  4. Travelers (US.TRU)&nbsp
  5. Coca-Cola (US,KO): The company has a bright future ahead of it now that its supply chain costs are coming down, Cramer said.


jim cramer picks 7 dow stocks that investors should consider owning 2022